HC Wainwright & Co. Maintains Buy on PMV Pharma, Lowers Price Target to $36
HC Wainwright & Co. analyst Robert Burns maintains PMV Pharma (NASDAQ:PMVP) with a Buy and lowers the price target from $63 to $36.
PMV Pharmaceuticals Q2 EPS $(0.38) Down From $(0.29) YoY
PMV Pharmaceuticals (NASDAQ:PMVP) reported quarterly losses of $(0.38) per share. This is a 31.03 percent decrease over losses of $(0.29) per share from the same period last year.
PMV Pharma, Merck Ink Clinical Trial Collaboration For Combination Study In Solid Tumors
PMV Pharmaceuticals Inc (NASDAQ:PMVP) has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE:MRK) to evaluate PC14586…
Oppenheimer Maintains Outperform on PMV Pharma, Raises Price Target to $33
Oppenheimer analyst Jeff Jones maintains PMV Pharma (NASDAQ:PMVP) with a Outperform and raises the price target from $30 to $33.
79 Biggest Movers From Yesterday
Gainers
AeroClean Technologies, Inc. (NASDAQ: AERC) gained 154.7% to settle at $12.10 on Tuesday on continued strength after the FDA granted clearance for the company's pūrgo technology, classifying it as a class II medical device.
MV Pharmaceuticals Says Initial PC14586 Phase 1 Data Presented At ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With A P53 Y220C Mutation
PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation
Overall response rate (ORR) of 32% (8/25)
Stocks That Hit 52-Week Lows On Thursday
During the Thursday's session, 100 stocks hit new 52-week lows.